HOLX - Hologic Stock Price, News & Analysis

$40.60 0.41 (1.02 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$40.19
Today's Range$40.03 - $40.95
52-Week Range$35.76 - $46.80
Volume2.69 million shs
Average Volume2.74 million shs
Market Capitalization$11.59 billion
P/E Ratio19.9
Dividend YieldN/A
Beta0.93

About Hologic (NASDAQ:HOLX)

Hologic logoHologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women's health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays. It offers viral load assays for the quantitation of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human Immunodeficiency Virus-1 (HIV-1). The Breast Health products include breast imaging and related products and accessories, including digital mammography systems, computer-aided detection (CAD) and breast biopsy guidance systems. The GYN Surgical products include NovaSure Endometrial Ablation System and MyoSure Hysteroscopic Tissue Removal System. The Skeletal Health segment offers Discovery and Horizon X-ray bone densitometers and mini C-arm imaging systems.


Industry, Sector and Symbol:
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: Health Care Equipment
  • Sector: Medical
  • Symbol: NASDAQ:HOLX
  • CUSIP: 43644010
  • Web: www.hologic.com
Debt:
  • Debt-to-Equity Ratio: 0.78%
  • Current Ratio: 0.79%
  • Quick Ratio: 0.61%
Price-To-Earnings:
  • Trailing P/E Ratio: 19.9
  • Forward P/E Ratio: 19.15
  • P/E Growth: 1.94
Sales & Book Value:
  • Annual Sales: $3.06 billion
  • Price / Sales: 3.83
  • Cash Flow: $3.70 per share
  • Price / Cash: 10.96
  • Book Value: $9.66 per share
  • Price / Book: 4.20
Profitability:
  • Trailing EPS: $2.64
  • Net Income: $755.50 million
  • Net Margins: 24.70%
  • Return on Equity: 21.69%
  • Return on Assets: 7.20%
Misc:
  • Employees: 5,333
  • Outstanding Shares: 288,270,000
 

Frequently Asked Questions for Hologic (NASDAQ:HOLX)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) issued its quarterly earnings data on Wednesday, November, 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.49 by $0.01. The medical equipment provider had revenue of $802.90 million for the quarter, compared to analysts' expectations of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.52 EPS. View Hologic's Earnings History.

When will Hologic make its next earnings announcement?

Hologic is scheduled to release their next quarterly earnings announcement on Tuesday, January, 30th 2018. View Earnings Estimates for Hologic.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY18 earnings guidance on Wednesday, November, 8th. The company provided EPS guidance of $2.10-2.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.15. The company issued revenue guidance of $3.2-3.28 billion, compared to the consensus revenue estimate of $3.30 billion.Hologic also updated its Q1 guidance to $0.48-0.50 EPS.

Where is Hologic's stock going? Where will Hologic's stock price be in 2017?

13 brokers have issued 12-month target prices for Hologic's shares. Their forecasts range from $42.00 to $53.00. On average, they expect Hologic's share price to reach $47.54 in the next year. View Analyst Ratings for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:

  • 1. Needham & Company LLC analysts commented, "FDA’s latest monthly Mammography Quality Standards Act (MQSA) statistics were published on 11/1/17. The number of digital breast tomosynthesis (DBT) units increased by 143 during October which represents a 5.1% Y/Y increase. DBT unit penetration increased to 29.0% from 28.5% last month and facility penetration increased to 44.0% from 42.8% last month. More importantly, DBT units placements were up 5.1% in 10/17 vs. 10/16. Based on this, we think that HOLX’s Breast Health business could see improved growth in F1Q18." (11/3/2017)
  • 2. According to Zacks Investment Research, "Hologic has been trading below the broader industry over the last six months. Moreover, the lowered guidance suggests dull prospects. Furthermore, the blood screening divestiture is expected to impede the company’s growth momentum in the days ahead. Foreign currency headwinds and a competitive landscape also continue to pose challenges. On a positive note, Hologic is optimistic about the recent commercial launch of the Brevera breast biopsy system in the United States. The company has been witnessing strength in the molecular diagnostics and GYN Surgical businesses. Moreover, sales are driven by the company’s recent receipt of CE mark for its new Panther Fusion system and Panther Fusion assays for flu and respiratory testing." (10/31/2017)

Are investors shorting Hologic?

Hologic saw a increase in short interest in October. As of October 31st, there was short interest totalling 10,839,458 shares, an increase of 28.9% from the October 13th total of 8,411,957 shares. Based on an average daily trading volume, of 2,698,364 shares, the short-interest ratio is currently 4.0 days. Currently, 3.9% of the company's stock are short sold.

Who are some of Hologic's key competitors?

Who are Hologic's key executives?

Hologic's management team includes the folowing people:

  • Stephen P. MacMillan, Chairman of the Board, President, Chief Executive Officer
  • Robert W. McMahon, Chief Financial Officer
  • Sanjay Prabhakaran, Regional President - Asia
  • , Bio & Compensation - 
  • Peter J. Valenti III, Division President- Breast and Skeletal Health
  • Jan Verstreken, Regional President - Europe,Middle EastandAfrica(EMEA) and Canada
  • , Bio & Compensation - 
  • Thomas A. West, Division President- Diagnostics
  • Eric B. Compton, Chief Operating Officer
  • Michael J. Watts, Vice President, IR Contact Officer
  • , Bio & Compensation - 
  • John M. Griffin, General Counsel
  • Elaine S. Ullian, Lead Independent Director

Who owns Hologic stock?

Hologic's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Parnassus Investments CA (2.69%), Victory Capital Management Inc. (2.09%), Pictet Asset Management Ltd. (1.04%), Dimensional Fund Advisors LP (0.72%), American Century Companies Inc. (0.57%) and Segall Bryant & Hamill LLC (0.56%). Company insiders that own Hologic stock include David R Lavance Jr, Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Nancy Leaming, Peter J Valenti III and Sally Crawford. View Institutional Ownership Trends for Hologic.

Who sold Hologic stock? Who is selling Hologic stock?

Hologic's stock was sold by a variety of institutional investors in the last quarter, including Highbridge Capital Management LLC, American Century Companies Inc., Skandinaviska Enskilda Banken AB publ, Cornerstone Capital Management Holdings LLC., State of Tennessee Treasury Department, Neuberger Berman Group LLC, Prudential Financial Inc. and Russell Investments Group Ltd.. Company insiders that have sold Hologic company stock in the last year include Elaine Ullian, Karleen Marie Oberton, Lawrence M Levy, Peter J Valenti III and Sally Crawford. View Insider Buying and Selling for Hologic.

Who bought Hologic stock? Who is buying Hologic stock?

Hologic's stock was bought by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Point72 Asset Management L.P., Pictet Asset Management Ltd., Victory Capital Management Inc., First Trust Advisors LP, Quantbot Technologies LP, State of Wisconsin Investment Board and Wedge Capital Management L L P NC. View Insider Buying and Selling for Hologic.

How do I buy Hologic stock?

Shares of Hologic can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Hologic's stock price today?

One share of Hologic stock can currently be purchased for approximately $40.60.

How big of a company is Hologic?

Hologic has a market capitalization of $11.59 billion and generates $3.06 billion in revenue each year. The medical equipment provider earns $755.50 million in net income (profit) each year or $2.64 on an earnings per share basis. Hologic employs 5,333 workers across the globe.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]


MarketBeat Community Rating for Hologic (HOLX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  537 (Vote Outperform)
Underperform Votes:  370 (Vote Underperform)
Total Votes:  907
MarketBeat's community ratings are surveys of what our community members think about Hologic and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Hologic (NASDAQ:HOLX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 4 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.69)
Consensus Price Target: $47.54 (17.09% upside)

Consensus Price Target History for Hologic (NASDAQ:HOLX)

Price Target History for Hologic (NASDAQ:HOLX)

Analysts' Ratings History for Hologic (NASDAQ:HOLX)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/9/2017Piper Jaffray CompaniesReiterated RatingBuy$48.00N/AView Rating Details
11/3/2017Needham & Company LLCReiterated RatingBuy$50.00N/AView Rating Details
10/10/2017Jefferies Group LLCReiterated RatingBuy$49.00 -> $44.00N/AView Rating Details
10/9/2017Stifel NicolausReiterated RatingBuy -> Buy$48.00 -> $45.00N/AView Rating Details
9/22/2017Royal Bank Of CanadaReiterated RatingHold$42.00LowView Rating Details
8/9/2017Barclays PLCReiterated RatingEqual Weight$53.00 -> $51.00LowView Rating Details
8/3/2017Deutsche Bank AGLower Price TargetBuy$51.00 -> $49.00MediumView Rating Details
8/3/2017Goldman Sachs Group, Inc. (The)DowngradeConviction-Buy -> Buy$48.00 -> $47.00HighView Rating Details
7/21/2017Bank of America CorporationReiterated RatingNeutral$44.00 -> $48.00LowView Rating Details
5/14/2017BTIG ResearchReiterated RatingBuy$47.00LowView Rating Details
5/9/2017Canaccord GenuityReiterated RatingBuy$53.00LowView Rating Details
3/30/2017Leerink SwannReiterated RatingOutperform$52.00LowView Rating Details
1/4/2017Evercore ISIDowngradeBuy -> Hold$42.00N/AView Rating Details
7/28/2016Morgan StanleyBoost Price TargetEqual Weight$38.00 -> $40.00N/AView Rating Details
1/31/2016William BlairReiterated RatingOutperformN/AView Rating Details
1/28/2016J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Hologic (NASDAQ:HOLX)

Earnings by Quarter for Hologic (NASDAQ:HOLX)

Earnings History by Quarter for Hologic (NASDAQ HOLX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/30/2018N/AView Earnings Details
11/8/2017Q4 2017$0.49$0.50$792.54 million$802.90 millionViewN/AView Earnings Details
8/2/2017Q3 2017$0.49$0.50$799.70 million$806.10 millionViewListenView Earnings Details
5/10/2017Q2 17$0.46$0.50$685.24 million$715.40 millionViewN/AView Earnings Details
2/1/2017Q117$0.51$0.52$725.01 million$734.40 millionViewListenView Earnings Details
11/2/2016Q416$0.50$0.52$721.52 million$726.80 millionViewN/AView Earnings Details
7/27/2016Q316$0.48$0.51$703.66 million$717.40 millionViewListenView Earnings Details
4/27/2016Q216$0.46$0.47$686.82 million$693.30 millionViewListenView Earnings Details
1/27/2016Q116$0.42$0.46$688.68 million$695.20 millionViewListenView Earnings Details
11/4/2015Q415$0.42$0.43$691.94 million$702.80 millionViewListenView Earnings Details
7/29/2015Q315$0.39$0.43$653.85 million$693.90 millionViewListenView Earnings Details
4/29/2015Q215$0.39$0.41$646.49 million$655.50 millionViewN/AView Earnings Details
1/28/2015Q115$0.36$0.39$630.79 million$652.80 millionViewListenView Earnings Details
11/5/2014Q414$0.37$0.43$636.20 million$660.60 millionViewListenView Earnings Details
7/30/2014Q314$0.34$0.37$621.89 million$632.60 millionViewListenView Earnings Details
4/30/2014Q214$0.33$0.37$609.35 million$625.00 millionViewListenView Earnings Details
2/3/2014Q114$0.31$0.34$609.65 million$612.40 millionViewListenView Earnings Details
11/11/2013Q413$0.37$0.39$624.40 million$622.10 millionViewListenView Earnings Details
8/5/2013Q3 2013$0.37$0.38$627.05 million$626.10 millionViewListenView Earnings Details
5/6/2013Q2 2013$0.34$0.35$639.53 million$619.10 millionViewListenView Earnings Details
2/4/2013Q1 2013$0.37$0.38$646.52 million$644.60 millionViewListenView Earnings Details
11/12/2012Q412$0.36$0.37$581.12 million$600.20 millionViewN/AView Earnings Details
7/30/2012$0.34$0.35ViewN/AView Earnings Details
4/30/2012$0.33$0.33ViewN/AView Earnings Details
1/30/2012$0.32$0.34ViewN/AView Earnings Details
11/7/2011$0.33$0.34ViewN/AView Earnings Details
8/1/2011$0.32$0.32ViewN/AView Earnings Details
5/2/2011$0.28$0.30ViewN/AView Earnings Details
1/31/2011$0.28$0.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Hologic (NASDAQ:HOLX)
2017 EPS Consensus Estimate: $2.00
2018 EPS Consensus Estimate: $2.12
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$0.50$0.51$0.51
Q2 20173$0.46$0.53$0.49
Q3 20173$0.48$0.54$0.50
Q4 20174$0.49$0.55$0.51
Q1 20183$0.49$0.52$0.50
Q2 20183$0.51$0.52$0.52
Q3 20183$0.54$0.57$0.55
Q4 20183$0.53$0.58$0.55
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Hologic (NASDAQ:HOLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Hologic (NASDAQ HOLX)

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 97.72%
Insider Trades by Quarter for Hologic (NASDAQ:HOLX)
Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Insider Trades by Quarter for Hologic (NASDAQ HOLX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/20/2017Karleen Marie ObertonVPSell1,023$39.84$40,756.32View SEC Filing  
11/13/2017Elaine UllianDirectorSell9,282$40.50$375,921.00View SEC Filing  
11/8/2017Karleen Marie ObertonVPSell1,256$39.29$49,348.24View SEC Filing  
11/6/2017Karleen Marie ObertonVPSell538$39.40$21,197.20View SEC Filing  
10/10/2017Lawrence M LevyDirectorSell9,596$36.81$353,228.76View SEC Filing  
10/9/2017Lawrence M LevyDirectorSell7,138$37.38$266,818.44View SEC Filing  
9/7/2017Lawrence M. LevyDirectorSell7,139$39.04$278,706.56View SEC Filing  
8/3/2017Elaine UllianDirectorSell6,902$40.12$276,908.24View SEC Filing  
7/17/2017Karleen Marie ObertonVPSell4,704$45.19$212,573.76View SEC Filing  
7/3/2017Elaine UllianDirectorSell8,849$45.28$400,682.72View SEC Filing  
6/7/2017Lawrence M LevyDirectorSell2,960$44.54$131,838.40View SEC Filing  
6/2/2017Elaine UllianDirectorSell8,938$43.99$393,182.62View SEC Filing  
5/30/2017Peter J Valenti IIIInsiderSell10,005$43.44$434,617.20View SEC Filing  
5/24/2017Lawrence M LevyDirectorSell9,193$42.93$394,655.49View SEC Filing  
5/17/2017Lawrence M LevyDirectorSell9,076$42.80$388,452.80View SEC Filing  
5/10/2017Lawrence M LevyDirectorSell9,837$45.34$446,009.58View SEC Filing  
5/3/2017Lawrence M LevyDirectorSell10,203$45.00$459,135.00View SEC Filing  
4/26/2017Lawrence M LevyDirectorSell10,374$44.46$461,228.04View SEC Filing  
4/24/2017Sally CrawfordDirectorSell16,969$44.00$746,636.00View SEC Filing  
4/19/2017Lawrence M LevyDirectorSell10,836$42.49$460,421.64View SEC Filing  
4/12/2017Lawrence M LevyDirectorSell10,757$42.45$456,634.65View SEC Filing  
4/3/2017Elaine UllianDirectorSell9,104$42.40$386,009.60View SEC Filing  
3/8/2017Sally CrawfordDirectorSell17,396$42.00$730,632.00View SEC Filing  
2/3/2017Elaine UllianDirectorSell9,423$39.54$372,585.42View SEC Filing  
11/21/2016Karleen Marie ObertonVPSell3,023$38.32$115,841.36View SEC Filing  
11/15/2016Karleen Marie ObertonVPSell1,211$36.55$44,262.05View SEC Filing  
11/8/2016Karleen Marie ObertonVPSell984$38.57$37,952.88View SEC Filing  
11/7/2016Karleen Marie ObertonVPSell522$38.53$20,112.66View SEC Filing  
10/10/2016Elaine UllianDirectorSell18,236$39.88$727,251.68View SEC Filing  
10/10/2016Karleen Marie ObertonVPSell31,470$40.00$1,258,800.00View SEC Filing  
7/21/2016Nancy LeamingDirectorSell8,179$37.00$302,623.00View SEC Filing  
7/11/2016Nancy LeamingDirectorSell6,221$36.04$224,204.84View SEC Filing  
6/1/2016Lawrence M LevyDirectorSell17,794$34.41$612,291.54View SEC Filing  
5/27/2016Peter J Valenti IIIInsiderSell10,022$33.83$339,044.26View SEC Filing  
5/26/2016Elaine UllianDirectorSell6,896$33.85$233,429.60View SEC Filing  
5/26/2016Karleen Marie ObertonVPSell4,228$33.85$143,117.80View SEC Filing  
2/24/2016David R Lavance JrDirectorSell11,621$34.50$400,924.50View SEC Filing  
11/10/2015Lawrence M. LevyDirectorSell20,000$40.70$814,000.00View SEC Filing  
9/21/2015Lawrence M. LevyDirectorSell5,000$42.02$210,100.00View SEC Filing  
9/8/2015Wayne WilsonDirectorSell100,000$39.00$3,900,000.00View SEC Filing  
8/28/2015Wayne WilsonDirectorSell11,146$39.70$442,496.20View SEC Filing  
8/26/2015Wayne WilsonDirectorSell25,080$38.61$968,338.80View SEC Filing  
8/14/2015Wayne WilsonDirectorSell13,257$42.20$559,445.40View SEC Filing  
6/3/2015Lawrence M LevyDirectorSell10,000$36.45$364,500.00View SEC Filing  
5/22/2015Lawrence M LevyDirectorSell5,000$35.05$175,250.00View SEC Filing  
5/4/2015Lawrence M LevyDirectorSell10,000$34.36$343,600.00View SEC Filing  
3/6/2015David R Lavance JrDirectorSell12,000$32.12$385,440.00View SEC Filing  
2/13/2015David R Lavance JrDirectorSell8,000$30.32$242,560.00View SEC Filing  
1/29/2015Karleen Marie ObertonVPSell18,997$30.00$569,910.00View SEC Filing  
11/11/2014Karleen Marie ObertonVPSell2,609$26.30$68,616.70View SEC Filing  
11/3/2014Karleen Marie ObertonVPSell12,507$26.83$335,562.81View SEC Filing  
10/31/2014Roger D MillsSVPSell14,506$26.00$377,156.00View SEC Filing  
9/9/2014Elaine UllianDirectorBuy7,900$25.36$200,344.00View SEC Filing  
5/9/2014Rohan HastieSVPSell6,037$24.36$147,061.32View SEC Filing  
5/8/2014Glenn MuirCFOSell50,000$24.26$1,213,000.00View SEC Filing  
5/6/2014Glenn MuirCFOSell196,000$23.29$4,564,840.00View SEC Filing  
5/6/2014Lawrence LevyDirectorSell5,052$23.58$119,126.16View SEC Filing  
5/6/2014Robert LavalleeCAOSell22,796$23.58$537,529.68View SEC Filing  
3/14/2014David Lavance, Jr.DirectorSell5,500$21.49$118,195.00View SEC Filing  
3/14/2014Glenn MuirCFOSell160,000$21.51$3,441,600.00View SEC Filing  
3/7/2014Mark CaseyCAOSell3,251$22.53$73,245.03View SEC Filing  
2/11/2014Stephen MacmillanCEOBuy38,600$21.58$832,988.00View SEC Filing  
2/7/2014Stephen MacmillanCEOBuy198,900$20.78$4,133,142.00View SEC Filing  
12/13/2013Robert LavalleeCAOSell15,677$21.70$340,190.90View SEC Filing  
10/30/2013Glenn P MuirCFOSell140,000$22.32$3,124,800.00View SEC Filing  
10/15/2013Glenn P MuirCFOSell28,000$22.12$619,360.00View SEC Filing  
9/16/2013Glenn MuirCFOSell28,000$20.45$572,600.00View SEC Filing  
9/13/2013Robert LavalleeCAOSell2,500$20.33$50,825.00View SEC Filing  
8/20/2013David BradySVPSell42,328$22.80$965,078.40View SEC Filing  
8/15/2013Glenn MuirCFOSell28,000$22.49$629,720.00View SEC Filing  
8/8/2013Lawrence LevyDirectorSell5,000$22.50$112,500.00View SEC Filing  
8/8/2013Mark CaseyCAOSell14,804$22.57$334,126.28View SEC Filing  
7/19/2013Robert H LavalleeCAOSell11,254$20.89$235,096.06View SEC Filing  
7/15/2013Glenn P MuirCFOSell28,000$19.78$553,840.00View SEC Filing  
7/1/2013Robert CascellaCEOSell20,000$19.55$391,000.00View SEC Filing  
6/17/2013Glenn P MuirCFOSell28,000$21.42$599,760.00View SEC Filing  
6/3/2013Robert CascellaCEOSell20,000$20.71$414,200.00View SEC Filing  
2/25/2013Lawrence M LevyDirectorSell5,000$22.00$110,000.00View SEC Filing  
9/5/2012Glenn P MuirCFOSell68,750$19.96$1,372,250.00View SEC Filing  
8/8/2012Glenn P MuirCFOSell68,750$19.69$1,353,687.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Hologic (NASDAQ HOLX)

Source:
DateHeadline
Karleen Marie Oberton Sells 1,023 Shares of Hologic, Inc. (HOLX) StockKarleen Marie Oberton Sells 1,023 Shares of Hologic, Inc. (HOLX) Stock
www.americanbankingnews.com - November 21 at 9:34 PM
Hologic Inc (HOLX) Files 10-K for the Fiscal Year Ended on September 30, 2017Hologic Inc (HOLX) Files 10-K for the Fiscal Year Ended on September 30, 2017
finance.yahoo.com - November 21 at 7:38 PM
$782.88 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter$782.88 Million in Sales Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - November 17 at 2:08 PM
Hologic, Inc. (HOLX) Director Elaine Ullian Sells 9,282 SharesHologic, Inc. (HOLX) Director Elaine Ullian Sells 9,282 Shares
www.americanbankingnews.com - November 15 at 8:22 PM
Hologic Announces Upcoming Put Option and Notice of Redemption of 2.00% Convertible Senior Notes Due 2043Hologic Announces Upcoming Put Option and Notice of Redemption of 2.00% Convertible Senior Notes Due 2043
finance.yahoo.com - November 14 at 8:04 PM
Hologic IncHologic Inc
www.bloomberg.com - November 13 at 7:34 PM
FY2018 EPS Estimates for Hologic, Inc. Decreased by Gabelli (HOLX)FY2018 EPS Estimates for Hologic, Inc. Decreased by Gabelli (HOLX)
www.americanbankingnews.com - November 13 at 8:20 AM
Q3 2018 EPS Estimates for Hologic, Inc. (HOLX) Boosted by Jefferies GroupQ3 2018 EPS Estimates for Hologic, Inc. (HOLX) Boosted by Jefferies Group
www.americanbankingnews.com - November 13 at 7:26 AM
Edited Transcript of HOLX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of HOLX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 11 at 9:36 AM
Hologic, Inc. (HOLX) Short Interest Up 28.9% in OctoberHologic, Inc. (HOLX) Short Interest Up 28.9% in October
www.americanbankingnews.com - November 11 at 3:40 AM
Brokers Set Expectations for Hologic, Inc.s FY2019 Earnings (HOLX)Brokers Set Expectations for Hologic, Inc.'s FY2019 Earnings (HOLX)
www.americanbankingnews.com - November 10 at 7:20 PM
Hologic, Inc. (HOLX) Expected to Post Q1 2018 Earnings of $0.49 Per ShareHologic, Inc. (HOLX) Expected to Post Q1 2018 Earnings of $0.49 Per Share
www.americanbankingnews.com - November 10 at 10:30 AM
Hologic, Inc. (HOLX) to Post Q1 2018 Earnings of $0.49 Per Share, Jefferies Group ForecastsHologic, Inc. (HOLX) to Post Q1 2018 Earnings of $0.49 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - November 10 at 10:30 AM
Karleen Marie Oberton Sells 1,256 Shares of Hologic, Inc. (HOLX) StockKarleen Marie Oberton Sells 1,256 Shares of Hologic, Inc. (HOLX) Stock
www.americanbankingnews.com - November 9 at 7:52 PM
Hologic, Inc. (HOLX) Given "Buy" Rating at Piper Jaffray CompaniesHologic, Inc. (HOLX) Given "Buy" Rating at Piper Jaffray Companies
www.americanbankingnews.com - November 9 at 1:54 PM
Hologic, Inc. (HOLX) Releases Quarterly  Earnings Results, Beats Expectations By $0.01 EPSHologic, Inc. (HOLX) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - November 9 at 12:22 AM
Hologic, Inc. (HOLX) Updates Q1 Earnings GuidanceHologic, Inc. (HOLX) Updates Q1 Earnings Guidance
www.americanbankingnews.com - November 8 at 10:46 PM
Hologic, Inc. (HOLX) Releases FY18 Earnings GuidanceHologic, Inc. (HOLX) Releases FY18 Earnings Guidance
www.americanbankingnews.com - November 8 at 10:46 PM
Hologic Inc Earnings Decline 2% In Q4 - NasdaqHologic Inc Earnings Decline 2% In Q4 - Nasdaq
www.nasdaq.com - November 8 at 8:30 PM
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2017Hologic Announces Financial Results for Fourth Quarter of Fiscal 2017
finance.yahoo.com - November 8 at 8:30 PM
Hologic tops Street 4Q forecastsHologic tops Street 4Q forecasts
finance.yahoo.com - November 8 at 8:30 PM
Hologic shares down 6% after lower fiscal 2018 sales forecastHologic shares down 6% after lower fiscal 2018 sales forecast
finance.yahoo.com - November 8 at 8:30 PM
Hologic, Inc. to Host Earnings CallHologic, Inc. to Host Earnings Call
finance.yahoo.com - November 8 at 3:18 PM
Anemic Quant Score Hamper Hologic (HOLX) Rating - Investorplace.comAnemic Quant Score Hamper Hologic (HOLX) Rating - Investorplace.com
investorplace.com - November 8 at 9:44 AM
Karleen Marie Oberton Sells 538 Shares of Hologic, Inc. (HOLX) StockKarleen Marie Oberton Sells 538 Shares of Hologic, Inc. (HOLX) Stock
www.americanbankingnews.com - November 7 at 7:37 PM
Anemic Quant Score Hamper Hologic (HOLX) RatingAnemic Quant Score Hamper Hologic (HOLX) Rating
investorplace.com - November 7 at 6:19 PM
Hologic to Webcast Presentations at Upcoming Investor ConferencesHologic to Webcast Presentations at Upcoming Investor Conferences
finance.yahoo.com - November 7 at 2:38 AM
Hologics (HOLX) "Buy" Rating Reaffirmed at Needham & Company LLCHologic's (HOLX) "Buy" Rating Reaffirmed at Needham & Company LLC
www.americanbankingnews.com - November 3 at 6:32 PM
Hologic, Inc. – Value Analysis (NASDAQ:HOLX) : November 2, 2017Hologic, Inc. – Value Analysis (NASDAQ:HOLX) : November 2, 2017
finance.yahoo.com - November 3 at 7:03 AM
Hologic, Inc. (HOLX) Receives Consensus Recommendation of "Buy" from BrokeragesHologic, Inc. (HOLX) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 2 at 8:42 AM
Hologic Launches the MyoSure® MANUAL Device to Help Doctors Remove Intrauterine Tissue In-OfficeHologic Launches the MyoSure® MANUAL Device to Help Doctors Remove Intrauterine Tissue In-Office
finance.yahoo.com - November 2 at 12:39 AM
Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : November 1, 2017Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : November 1, 2017
finance.yahoo.com - November 2 at 12:39 AM
Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?
finance.yahoo.com - November 2 at 12:39 AM
Hologic, Inc. (HOLX) Scheduled to Post Quarterly Earnings on WednesdayHologic, Inc. (HOLX) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - November 1 at 5:42 AM
Hologic, Inc. (HOLX) Upgraded to Hold at Zacks Investment ResearchHologic, Inc. (HOLX) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 31 at 4:16 PM
Hologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion Paraflu Assay - StreetInsider.comHologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion Paraflu Assay - StreetInsider.com
www.streetinsider.com - October 28 at 6:36 AM
Hologic, Inc. (HOLX) Expected to Announce Quarterly Sales of $792.51 MillionHologic, Inc. (HOLX) Expected to Announce Quarterly Sales of $792.51 Million
www.americanbankingnews.com - October 27 at 10:40 AM
Hologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion Paraflu AssayHologic (HOLX) Receives 510(k) Clearance from FDA for its Panther Fusion Paraflu Assay
www.streetinsider.com - October 27 at 6:18 AM
Interesting HOLX Put And Call Options For June 2018Interesting HOLX Put And Call Options For June 2018
www.nasdaq.com - October 27 at 6:18 AM
Paraflu Assay Now FDA Cleared on Hologics New Panther Fusion® SystemParaflu Assay Now FDA Cleared on Hologic's New Panther Fusion® System
finance.yahoo.com - October 26 at 11:25 AM
$0.49 EPS Expected for Hologic, Inc. (HOLX) This Quarter$0.49 EPS Expected for Hologic, Inc. (HOLX) This Quarter
www.americanbankingnews.com - October 25 at 2:00 PM
ETFs with exposure to Hologic, Inc. : October 23, 2017ETFs with exposure to Hologic, Inc. : October 23, 2017
finance.yahoo.com - October 23 at 7:08 PM
Hologic, Inc. (HOLX) Downgraded to Sell at Zacks Investment ResearchHologic, Inc. (HOLX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - October 23 at 3:08 PM
Contrasting Hologic (HOLX) & The CompetitionContrasting Hologic (HOLX) & The Competition
www.americanbankingnews.com - October 22 at 10:18 PM
How The Parts Add Up: QQXT Headed For $52How The Parts Add Up: QQXT Headed For $52
www.nasdaq.com - October 21 at 6:38 PM
15 Cheap Stocks That Could Launch the Next Big Thing15 Cheap Stocks That Could Launch the 'Next Big Thing'
finance.yahoo.com - October 19 at 2:34 AM
Head to Head Comparison: Hologic (HOLX) and Its PeersHead to Head Comparison: Hologic (HOLX) and Its Peers
www.americanbankingnews.com - October 17 at 10:26 PM
Hologic, Inc. (HOLX) Downgraded by Zacks Investment Research to SellHologic, Inc. (HOLX) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - October 17 at 3:32 PM
Q1 2018 Earnings Forecast for Hologic, Inc. Issued By Leerink Swann (HOLX)Q1 2018 Earnings Forecast for Hologic, Inc. Issued By Leerink Swann (HOLX)
www.americanbankingnews.com - October 16 at 5:38 AM
Analyzing Hologic (HOLX) & Its RivalsAnalyzing Hologic (HOLX) & Its Rivals
www.americanbankingnews.com - October 16 at 2:10 AM

Social Media

Financials

Chart

Hologic (NASDAQ HOLX) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.